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Phort-Term Change in Distance Walked
n 6 Min Is an Indicator of Outcome in Patients
ith Chronic Heart Failure in Clinical Practice
ndrea Passantino, MD, Rocco Lagioia, MD, Filippo Mastropasqua, MD, Domenico Scrutinio, MD
ari, Italy
OBJECTIVES The purpose of this study was to investigate the prognostic value of change in distance walked
in 6 min in chronic heart failure (CHF).
BACKGROUND The strongest indication for the 6-min walking test (6MWT) is for measuring the response
to therapeutic interventions in patients with CHF. Whether the increase in distance walked
after a therapeutic intervention translates into improved clinical outcome is largely unknwon.
METHODS We studied 476 CHF patients with left ventricular systolic dysfunction who were referred to
our institution for adjustment of heart failure therapy because of persisting or worsening
symptoms. Adjustment of therapy involved four classes of drugs: angiotensin-converting
enzyme inhibitors or angiotensin II receptor blockers, beta-blockers, loop diuretics, and
aldosterone antagonists. A standardized 6MWT was performed at baseline and at discharge.
RESULTS After 15.2  8 days, the distance walked increased from 326  107 m to 408  109 m
(25%; p  0.001). During a mean follow-up of 23.9 months, 94 patients died and 12
patients underwent cardiac transplantation. Among a set of variables, New York Heart
Association functional class (p  0.02), serum creatinine concentration (p  0.01), left
ventricular ejection fraction (p  0.002), distance walked at baseline (p  0.0002), and
change in distance walked (p  0.002) were significant independent predictors of survival.
When the patients were divided into two subgroups according to the median value of the
distance walked at baseline, the increase in walking distance was significantly associated with
survival only in the subgroup of patients who walked 340 m at baseline.
CONCLUSIONS Our data indicate that repeating a 6MWT after drug intervention provides independent
prognostic information in CHF patients with more compromised exercise capacity. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.061Coll Cardiol 2006;48:99–105) © 2006 by the American College of Cardiology Foundation
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ohe 6-min walking test (6MWT) is an easy to administer,
afe, and inexpensive test reflective of daily life activities
hich can be performed by the majority of patients with
hronic heart failure (CHF) (1,2). The 6MWT is widely
sed as a measure of functional status of patients with
HF (1). It has also been shown to provide prognostic
nformation in several studies and has repeatedly been
ompared with cardiopulmonary exercise testing, although
he information provided by the 6MWT and cardiopulmo-
ary exercise testing should be considered complementary
ather than duplicative (2–4). The strongest indication for
he 6MWT is to measure the response to therapeutic
nterventions in patients with moderate to severe heart
ailure (4). Accordingly, it has also been used as a primary
nd point in clinical trials. In the clinical setting, a relevant
uestion after pre- and post-treatment tests have been
ompleted is whether the improvement in distance walked
ranslates into fewer hospitalizations or improved survival.
ata on such a relationship are still scarce. In the Cardiac
esynchronization in Chronic Heart Failure trial (5), the
MWT was a primary end point. The patients assigned to
ardiac resynchronization had a statistically significant im-
rovement in the distance walked in 6 min, which was
From the Division of Cardiology and Cardiac Rehabilitation, IRCCS Fondazione
alvatore Maugeri, Institute of Cassano Murge, Bari, Italy.6
Manuscript received November 29, 2005; revised manuscript received January 18,
006, accepted February 17, 2006.pparent as early as after four weeks. Interestingly, such an
mprovement was followed by fewer deaths and a statisti-
ally significant lower risk of death or worsening heart
ailure requiring hospitalization during the follow-up.
The present study was undertaken to investigate the clinical
ignificance of the change in the distance walked in 6 min after
herapeutic intervention in a large population of patients with
HF due to left ventricular systolic dysfunction.
ETHODS
tudy population. We studied 488 patients with CHF
ho were referred to our institution from other hospitals or
y general practitioners for adjustment of heart failure
herapy because of persisting or worsening symptoms and/or
or clinical evaluation, even for their potential candidacy for
eart transplantation. The following prospective selection
riteria were used. Patients were included if they had
ymptoms of heart failure and a left ventricular ejection
raction (LVEF) of 40%, as assessed by two-dimensional
chocardiography. Patients with recent myocardial infarc-
ion (3 months), angina pectoris- or exercise-induced
yocardial ischemia, surgically uncorrected valvular or con-
enital heart disease, suspected active myocarditis, obstruc-
ive, hypertrophic or restrictive cardiomyopathy, clinical
anifestations of peripheral or cerebrovascular disease, or
ther noncardiac diseases limiting the ability to perform a
MWT were excluded.
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6-Min Walking Test in Heart Failure July 4, 2006:99–105Adjustment of therapy during hospitalization principally
nvolved four classes of drugs: angiotensin-converting en-
yme inhibitors (ACEIs) or angiotensin II receptor blockers
ARBs), beta-blockers, loop diuretics (furosemide), and
ldosterone antagonists. During hospitalization, treatment
ith ACEIs, ARBs, or both and beta-blockers was imple-
ented or titrated to maximally tolerated dose by the
n-hospital referring heart failure specialist. Furosemide was
rescribed as needed, either orally or intravenously, and the
ose personalized to obtain the maximal relief of symptoms
nd improvement of congestive state. At discharge, ACEIs
nd/or ARBs were prescribed to 441 patients (92.6%),
eta-blockers to 338 (71%), furosemide to 403 (84.7%), and
pironolactone to 218 (45.8%). A combination of ACEIs or
RBs and beta-blockers was prescribed to 310 patients
65%). Enalapril and ramipril were the most frequently
rescribed ACEIs; their median daily dosage was 20 mg and
mg, respectively. The following beta-blockers (number of
atients; percentage of the recommended dose) were pre-
cribed: carvedilol (n  315; 32% of 50 mg daily), meto-
rolol (n  15; 55% of 200 mg daily), and bisoprolol,
tenolol, or sotalol for the remaining 8 patients. The median
aily dosages of furosemide and spironolactone were 50 mg
nd 25 mg, respectively. A rehabilitative intervention, prin-
ipally aimed at preventing functional deterioration during
ospitalization, was also offered to all patients. Each par-
icipant was given a low-intensity individual exercise pro-
ram, supervised by a physiotherapist, consisting of respi-
atory, mobilization, musculoskeletal flexibility, movement
oordination, and/or callisthenic exercises performed in 2 to
sessions daily, for 15 to 30 min at each session, 5 times per
eek. In more severely ill patients, such a program was
tarted once symptoms at rest had subsided. During each
ession, heart rate and rhythm, symptoms, and perceived
xertion were monitored.
The study was approved by the local institutional review
oard, and a standard informed consent to 6MWT and
ardiopulmonary exercise test was obtained from all patients.
ix-minute walking test. The walking test was performed
n an indoor unobstructed 60-m long corridor, according to
he recommendations of Guyatt et al. (6) and the American
horacic Society (4). All patients were informed in a
tandarzided manner of the purpose and method of the test
efore the test was performed. They were instructed to walk
he corridor from one end to the other at their own pace, as
Abbreviations and Acronyms
6MWT  6-min walking test
ACEI  angiotensin-converting enzyme inhibitor
ARB  angiotensin II receptor blockers
CHF  chronic heart failure
LVEF  left ventricular ejection fraction
VCO2  exercise carbon dioxide output
VO2  exercise oxygen consumptionany times as possible, in the permitted time. The patients sere advised on the possibility of slowing down the pace
nd stopping or resting as needed to resume walking as soon
s they felt they were able to do so. After 6 min had elapsed,
atients were instructed to stop walking, and the total
istance walked was measured. The test was supervised by a
hysical therapist who encouraged the patients in a stan-
ardized fashion at regular intervals. A baseline 6MWT was
erformed within 24 h of hospital admission or once
ymptoms at rest had subsided and fluid retention had
esolved, and a second test was performed at discharge.
ardiopulmonary exercise testing. Treadmill exercise test-
ng with expiratory gas analysis was performed using the
odified Bruce protocol (7). Patients were encouraged to
ontinue exercising until dyspnea or fatigue forced them to
top. Those patients who were not familiar with exercise
esting underwent a preliminary one. Oxygen uptake (VO2)
nd carbon dioxide output (VCO2) were measured breath-
y-breath by an automated system (System 2900; Sensor
edics, Anaheim, California). Measurements were taken at
est and every 20 s throughout exercise and recovery.
naerobic threshold was defined as the point at which the
espiratory exchange ratio (VCO2/VO2) was 1.00 or by the
-slope method (8). Peak VO2 was defined as the VO2
easured at the end of exercise. A total of 199 patients
41.8%) did not undergo cardiopulmonary exercise testing
uring the index hospitalization because of the severity of
orsening symptoms at entry, noncardiac reasons, or
efusal.
tatistical analysis. The primary end point was all-cause
ortality. The vital status was ascertained by interviewing
atients, their relatives, and/or treating physician or by
irect knowledge. In survival analysis, heart transplantation
as considered a censored event. Continuous variables are
xpressed as mean  standard deviation. To identify the
eterminants of change in distance walked, a forward
tepwise multivariable linear regression analysis was per-
ormed. The following variables were included in the
nalysis: age, gender, New York Heart Association
NYHA) functional class, LVEF, distance walked at base-
ine, time interval between baseline and the second 6MWT,
nd change in drug therapy. Survival curves were calculated
y the Kaplan-Meier method. Univariate and multivariate
urvival analyses were performed using the Cox proportional
azards regression model. The following variables were
onsidered in the univariate analysis: age, gender, NYHA
unctional class, LVEF, left bundle branch block, distance
alked at baseline, change in distance walked, peak VO2,
onsustained ventricular tachycardia on Holter monitoring,
emoglobin, serum sodium concentration, serum creatinine
oncentration, total cholesterol level, and treatment with
CEIs or beta-blockers at discharge. Variables with a
value of 0.1 at univariate analysis were entered into the
ultivariate Cox model. For survival analyses, continuous
ariables were dichotomized according to their median
alue. Analyses were performed using the SPSS version 8.0
tatistical package (SPSS Inc., Chicago, Illinois).
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July 4, 2006:99–105 6-Min Walking Test in Heart FailureESULTS
welve of the 488 patients were lost to follow-up. The
aseline characteristics of the remaining 476 patients are
eported in Table 1. Mean age was 63.6 11.9 years; 34.7%
f the patients were over 70 years old, and 79% were men.
schemic heart disease was the most frequent cause of heart
ailure (48.1%), followed by idiopathic dilated cardiomyop-
thy (38.7%), hypertension (7.4%), and surgically corrected
alvular disease (5.8%). Mean NYHA functional class and
VEF were 2.5  4 and 29.8  9.7%, respectively. Two
undred thirty-seven patients (49.7%) had severe left ven-
ricular dysfunction (LVEF 30%). Eighty-four patients
17.6%) were in atrial fibrillation, and 61 (13%) had an
mplanted cardioverter defibrillator. At baseline, 175
atients (36.8%) walked 300 m. Medication use is re-
orted in Table 2. Two hundred twenty-two patients
46.6%) were already on beta-blocker treatment at baseline,
72 (78.1%) on ACEIs and/or ARBs, and 388 (81.5%) on
urosemide. During hospitalization, beta-blocker treatment
as newly prescribed to 116 (24.3%), ACEIs or ARBs to 69
14.5%), and furosemide to 16 (3.4%) patients. In addition,
Table 1. Baseline Characteristics
M
Demographic
Age
70 yrs
Gender (male/female)
Clinical history
Diabetes
Hypertension
Chronic obstructive pulmonary disease
Previous cerebrovascular disease
Previous myocardial infarction
Previous CABG
Implantable cardioverter-defibrillator
Cardiovascular assessment
Cause of heart failure
Ischemic
Idiopatic dilated cardiomyopathy
Hypertensive
Surgically corrected valvular disease
Body mass index
NYHA functional class
LVEF (%)
LVEF 30%
6-min walking test
Distance walked at baseline (m) 3
300 m at baseline
Peak VO2 (ml/kg/min)
Atrial fibrillation
LBBB
NSVT at Holter monitoring
Biochemical measurements
Hemoglobin (g/dl)
Serum sodium concentration (mmol/l) 1
Serum creatinine concentration (mg/dl)
Total cholesterol level (mg/dl) 1
CABG  coronary artery bypass graft; LBBB  left bundle
nonsustained ventricular tachycardia; NYHA  New York Hhe daily dosage of beta-blockers was doubled and that of rCEIs or furosemide increased in 25.7% (57 of 222), 19.9%
74 of 372), and 21.9% (85 of 388) of the patients who were
lready treated with these drugs at hospital entry, respec-
ively. At baseline, only 199 patients (41.8%) were on
 SD Median Value n (%)
 11.9
164 (34.7)
376/100
75 (15.7)
193 (40.5)
47 (9)
20 (4)
209 (44)
106 (22)
61 (13)
229 (48.1)
184 (38.7)
35 (7.4)
28 (5.7)
 5.2
 4
 9.7 25
237 (49.8)
 107 340
175 (36.8)
 4.5
84 (17.6)
122 (25.2)
120 (25.2)
 1.8 13.6
 3.5 135
 0.5 1.2
 43 175
block; LVEF  left ventricular ejection fraction; NSVT 
Association; VO2  exercise oxygen consumption.
able 2. Medication Use
At Entry At Discharge
CEIs 306 (64.3) 375 (78.8)
Ramipril 166 (34.9) 203 (42.6)
Enalapril 131 (27.5) 147 (30.9)
Others 20 (4.2) 25 (5.3)
RBs 62 (13) 73 (15.3)
CEIs and/or ARBs 372 (78.1) 441 (92.6)
eta-blockers 222 (46.6) 338 (71)
Carvedilol 199 (41.8) 315 (66.2)
Metoprolol 15 (3.2) 15 (3.2)
Others 8 (1.7) 8 (1.7)
CEIs/ARBs or beta-blocker 308 (64.7) 465 (97.7)
CEIs/ARBs and beta-blocker 199 (41.8) 310 (65.1)
urosemide 388 (81.5) 403 (84.7)
ldosterone antagonists 146 (30.7) 218 (45.8)
tatins — 179 (37.8)
alues are n (%).ean
63.6
26.7
2.5
29.8
26.8
18.3
13.5
37.6
1.14
79.4ACEI  angiotensin-converting enzyme inhibitor; ARBs  angiotensin II
eceptor blockers.
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6-Min Walking Test in Heart Failure July 4, 2006:99–105reatment with the association of ACEIs/ARBs and beta-
lockers compared with 310 (65.1%) at discharge.
During a mean follow-up of 23.9 months, 94 patients
19.7%) died and 12 (2.5%) underwent cardiac transplantation.
Two hundred seventy-seven patients underwent cardio-
ulmonary exercise testing at a mean of 14  9 days after
ospitalization. Seventy-six, in whom the anaerobic thresh-
ld could not be detected, were excluded from the analysis.
n the remaining 201 patients, the attained peak VO2 was
8.3 4.5 ml/kg/min. During follow-up, 20 of them (10%)
ied and 7 (3.5%) underwent heart transplant.
ix-minute walking test. Baseline 6MWT was performed
t a mean of 2.4  3.8 days (median 1 day) after hospital-
zation. After a mean interval of 15.2  8 days between the
wo 6MWTs, the distance walked in 6 min increased from
26.8  107.1 m to 408.3  109.2 m (p  0.001), with a
ean increase of 81.5 56.3 m (25%). The median value
f the distance increase was 70 m. The rate of patients
alking 300 m decreased from 36.8% at baseline (175 of
76) to 12.8% at discharge (61 of 476) (p 0.001). Forward
tepwise regression analysis identified age (p  0.0001),
ale gender (p  0.001), distance walked at baseline (p 
.0001), and change in beta-blocker/ACEI therapy (i.e.,
ew prescription or increase in daily dosage of beta-blockers
nd ACEIs) (p  0.0001) as independent significant
redictors of the increase in distance walked. Age and
istance walked at baseline were inversely related to the
ncrease in distance walked.
nivariate survival analysis. The results of univariate anal-
sis are reported in Table 3. Age, NYHA functional class,
VEF, distance walked at baseline, change in distance
alked, hemoglobin, serum sodium concentration, serum
reatinine concentration, total cholesterol level, and treat-
ent with beta-blockers were significant univariate predic-
ors of prognosis. Survival was significantly better in patients
ho increased the distance walked in 6 min by more than
Table 3. Results of Univariate Cox Proportion
Reg
Coe
Age 65 yrs
Male gender 
NYHA functional class III/IV
LVEF 25%
LBBB
Distance walked at baseline 340 m
Change in distance walked 70 m
Peak VO2 14 ml/kg/min*
Nonsustained ventricular tachycardia 
Hemoglobin 13.6 g/dl
Serum sodium concentration 135 mmol/l
Serum creatinine concentration 1.2 mg/dl
Total cholesterol level 175 mg/dl
No beta-blockers at discharge
No ACEIs at discharge
*Analysis performed on 201 patients.
CI  confidence interval; other abbreviations as in Table0 m (median value) compared with those who did not
6
dFig. 1). The survival curves began to diverge as early as five
onths after and continued to diverge during the following
onths. When the patients were divided into two sub-
roups according to the median value of the distance walked
t the baseline test, change in walking distance was signif-
cantly associated with survival only in the subgroup who
alked 340 m at baseline (Fig. 2). Estimated survival
robability at 1, 2, and 3 years as a function of change in
istance walked is shown in Figure 3.
ultivariate survival analysis. Table 4 summarizes the
esults of the multivariate analysis. The NYHA functional
lass, serum creatinine concentration, LVEF, distance
alked at baseline, and change in distance walked were
ignificant independent prognostic predictors. According to
he Cox model, each 50-m between-test increment in
istance walked resulted in a 23% increased likelihood of
urvival. Change in distance walked remained an indepen-
ent and incremental predictor of prognosis (p  0.003),
ven after adjustment for continuous distance walked at
zards Survival Analysis
n
nt
Standard
Error
Hazard Ratio
(95% CI) p Value
0.21 2.1 (1.37–3.21) 0.00006
0.25 0.92 (0.56–1.52) 0.76
0.21 2.59 (1.70–3.94) 0.00001
0.21 2.53 (1.65–3.87) 0.00001
0.23 1.53 (0.95–2.45) 0.07
0.24 3.54 (2.19–5.72) 0.000001
0.22 1.87 (1.21–2.88) 0.0045
0.63 1.4 (0.41–5.15) 0.54
0.23 0.95 (0.59–1.52) 0.84
0.21 1.52 (1.00–2.29) 0.04
0.21 1.92 (1.26–2.92) 0.0023
0.20 2.61 (1.73–3.94) 0.00001
0.21 1.60 (1.06–2.43) 0.02
0.21 1.56 (1.03–2.36) 0.035
0.24 1.2 (0.74–1.94) 0.44
d 2.
igure 1. Survival according to the median value (70 m) of the increase inal Ha
ressio
fficie
0.74
0.07
0.95
0.93
0.42
1.27
0.62
0.38
0.04
0.42
0.65
0.96
0.48
0.44
0.18-min walking distance following drug intervention. Solid line  70 m;
otted line  70 m.
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July 4, 2006:99–105 6-Min Walking Test in Heart Failureaseline and change in beta-blocker/ACEI therapy by Cox
ultivariate analysis.
ISCUSSION
he 6MWT is widely applied in clinical and research
ettings for assessing functional status, prognosis, and the
esponse to therapeutic interventions in patients with CHF
1–4). A high concordance between change in distance
alked following therapeutic interventions and the results
f symptom assessment has been found in clinical trials (9).
ugck et al. (10) demonstrated that a change in 6MWT
redicts change in peak VO2. Moreover, Gualeni et al. (11)
howed 6MWT distance, but not peak VO2, to be sensitive
o short-term changes in drug therapy. Little is known
bout the relationship between change in walking distance
nd subsequent clinical outcome.
To our knowledge, this is the first study to investigate the
rognostic importance of the change in distance walked in
min in patients with CHF. Our data indicate that, in a
linical practice setting, short-term improvement in distance
alked after drug intervention is independently associated
ith improved survival. The rehabilitative intervention,
hough of low intensity, may have contributed to improving
ubmaximal exercise tolerance by preventing functional
eterioration that may result from prolonged hospitalization
igure 3. Estimated 1-year (solid line), 2-year (dotted line), and 3-year
igure 2. Survival according to the median value (70 m) of the increase in
ho walked 340 m (A) or 340 m (B) at baseline. Solid line  70 mh
dashed line) survival probability as a function of change in distance
alked in 6 min, according to univariate Cox model.r bedrest. Survival of the patients who increased distance
alked by more than 70 m (median value) was significantly
etter than that of patients who did not. At 1 and 2 years,
survival rate of 96% and 88% was observed in the former
ompared with 90% and 76% in the latter subgroup. Each
0-m between-test increment in distance walked resulted in
23% increased likelihood of survival. These data parallel
hose by Pinto-Plata et al. (12) in patients with severe
hronic obstructive pulmonary disease in whom a higher
ate of decline in walking distance independently predicted
higher mortality. It is important to note that the associ-
tion between change in walking distance and survival was
efinitely stronger among the more compromised patients,
.e., those who walked 340 m at baseline. Conversely, no
rognostic impact of change in distance walked was seen for
ess compromised patients. The observed significant inverse
elationship between distance walked at baseline and in-
rease in walking distance confirms this figure. This is in
ine with a recent review showing that the 6MWT may be
f greater value in patients with more advanced heart failure,
here it may function as a maximal exercise test (9,13).
uite surprisingly, in the subgroup of patients who under-
ent cardiopulmonary exercise testing, peak VO2 dichoto-
ized at 14 ml/kg/min was not statistically significant in
erms of predicting survival. However, it should be consid-
red that only 20 fatal events occurred in this subgroup and
hat 82% of the patients were being treated with beta-
locker therapy. Currently, the prognostic impact of peak
O2 and cut-off value of 14 ml/kg/min among patients
reated with beta-blockers is under close reevaluation
14,15).
Some key points of the present study are worth noting.
irst, apart from the seminal multicenter study of Bittner
t al. (16) including 833 patients, the present study is the
argest to date to look at the relationship between 6MWT
nd survival in CHF. Second, this was a single-center study
nd all the tests were administered in a standardized manner
y the same physical therapist to each patient, allowing for
omogeneity in test administration. Third, we observed a
ean increase in walking distance of 25%, which is far
nce walked following drug intervention in the two subgroups of patients
tted line  70 m.distaigher than the 10% threshold value required to confirm
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6-Min Walking Test in Heart Failure July 4, 2006:99–105ith 99% confidence that a real change has occurred (17).
inally, at discharge, beta-blockers were prescribed to 71%
f the patients and ACEIs and/or ARBs to 92.6%. Sixty-
ve percent of the patients received both beta-blockers and
CEIs and/or ARBs. These findings compare very favor-
bly with ACEI and beta-blocker prescription rate in
revious studies of heart failure in clinical practice (14,18–
2). The daily doses of these drugs in the present study are
n line with such studies (14,18–23).
From a general point of view, our findings may appear to
e inconsistent with those of clinical trials that, as a whole,
o not support a concordance between increased distance
alked and improved survival (9). Treatment with ACEIs
r beta-blockers, for example, is usually recognized as
aving a great impact on mortality and morbidity without
mproving exercise capacity (13), even though both ACEIs
nd beta-blockers were found to significantly improve sub-
aximal exercise tolerance, as assessed by the distance
alked in 6 min, in some studies (24–26). Perhaps a
oncordance between improved submaximal exercise capac-
ty and improved survival may be better appreciated with
ardiac resynchronization therapy (5,9). Some important
ifferences between clinical trials and our study should,
owever, be recognized. Whereas the patients included in
linical trials are in stable clinical conditions, background
herapy has been optimized, and the doses maintained
table before they are entered into the study, most of our
atients had persisting or worsening symptoms at admis-
ion, requiring a therapeutic intervention which involved
our classes of drugs. This implies a greater potential for
mprovement for patients included in our study. Actually,
he magnitude of the effect of therapy on distance walked in
ost clinical trials (9), expressed either as absolute value or
s percentage change, was substantially lower than what
e measured (81 m, 25%). Therefore, the magnitude of
he change may not have been large enough to allow a
ossible concordance between 6MWT results and survival
o be appreciated in clinical trials (9). Finally, the relation-
hip between change in distance walked and subsequent
linical outcome is difficult to specifically address in clinical
rials, because usually no serial tests are carried out and the
iming of the on-treatment 6MWT coincides with the end
f follow-up.
tudy limitations. We failed to have two repeated 6MWT
t baseline, and this may be a limitation of the study.
Table 4. Results of Multivariate Cox Proportio
Reg
Coe
NYHA functional class III/IV
Serum creatinine concentration 1.2 mg/dl
LVEF 25%
Distance walked at baseline 340 m
Change in distance walked 70 m
CI  confidence intervals; other abbreviations as in Table 1owever, the procedure of repeating the walking test may Me of discomfort for the patients, especially for those with
ore severely impaired functional capacity. In our study,
7% of patients walked less than 300 m at baseline, i.e., were
t the worst functional and prognostic level (16). Moreover,
he 6MWT has been found to be a reproducible measure in
HF in previous studies. A reproducibility of 0.96 was
bserved by Cahalin et al. (27) in patients with advanced
eart failure. O’Keefe et al. (28) found a reproducibility of
.91 in a population of very elderly and frail CHF patients,
.e., those very likely to present variability in distance
alked. Opasich et al. (17) and Rostagno et al. (29) found
hat the difference between two walking test measurements
erformed on the same day or on two consecutive days does
ot exceed 5%, setting a 10% threshold value for the
ccurrence of a real change (17). In our study, a 25%
ncrease in distance walked was observed. Finally, the
alidity of a single 6MWT has been confirmed in several
tudies (5,9,16,25,29), even in patients with advanced heart
ailure (27). Because individualized physical therapy could
ave contributed to the observed improvement in submaxi-
al exercise capacity, some caution is required in extrapo-
ating the prognostic utility of measuring change in distance
alked to other patients who receive medications only. In
ddition, in our study, an in-hospital 6MWT was repeated
fter a mean of 15 days; whether repeating 6MWT very
arly during a hospitalization or later, on an outpatient basis,
ould provide the same prognostic information remains
ndefined. Because classifying the cause of death by phone
nterview of patient relatives and/or treating physician could
e problematic, we assessed all-cause mortality, which,
owever, is an objective and unbiased end point. Moreover,
t should be acknowledged that patients were on average
ather young and the majority were men. Finally, we failed
o include other known predictors of prognosis in the
nalysis such as the degree of neurohumoral activation.
onclusions. In conclusion, our data indicate that repeat-
ng a 6MWT after drug intervention provides independent
rognostic information in CHF patients with more com-
romised exercise capacity, thus supporting the usefulness of
tandardized 6MWT in the process of multiparametric
ssessment of the effectiveness of therapeutic interventions
n clinical practice.
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